drugset / Trial / NCT02015351

Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study

NCT02015351

NaSingle-groupOpen-labelTreatment

Summary

Efficacy of monthly intravitreal anti-vascular endothelial growth factor (VEGF) associated to systemic immunosuppression in patients with Vogt-Koyanagi-Harada Disease and choroidal neovascularization. Minimum follow-up 12 months. Endpoints: 6 and 12 months of follow-up. Outcome measures: improvement of VA, decrease in central foveal thickness as measured by Optical Coherence Tomography (OCT) and absence of intra/subretinal fluid.

Timeline

Start
2012-09
Primary completion
2017-10
Completion
2018-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 1.25 mg Intravitreal